je.st
news
Tag: merck
Merck to Present at the Barclays Global Healthcare Conference
2015-03-10 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Robert Davis, executive vice president and chief financial officer, Merck, is scheduled to present at the Barclays Global Healthcare Conference in Miami on March 11, 2015 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/webcasts-and-presentations.html. About Merck Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: present
global
conference
healthcare
Hagens Berman Files Wrongful Death Lawsuit Against Merck for Suicide...
2015-03-10 04:06:54| Biotech - Topix.net
Consumer-rights law firm Hagens Berman is representing surviving family members in a wrongful death lawsuit against Merck & Co. , one of the largest pharmaceutical companies in the world, for allegedly failing to warn of dangerous side effects relating to suicidality and suicide ideation in its prescription hair loss drug Propecia.
Tags: files
death
suicide
lawsuit
Layoffs at Cubist come amid a steady flow of senior execs out of Merck
2015-03-07 10:48:14| Biotech - Topix.net
The layoffs announced in Lexington this week by the new owner of Cubist Pharmaceuticals come amid an outflow of high-ranking executives from the antibiotics company seeking new positions, according to local job placement experts. In recent days, local staffing firms who work in the life science industry confirmed that there have been a slew of calls from Cubist employees at all levels looking for new jobs in the three months since Merck & Co.
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
2015-03-05 00:30:00| Merck.com - Product News
Dateline City: TOKYO & KENILWORTH, N.J. Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, through a subsidiary, announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Mercks anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. Language: English Contact: Eisai Public Relations Department+81-(0)3-3817-5120orEisai Investor Relations+81-(0)3-3817-5327orMerck Media RelationsPamela Eisele, 267-305-3558or Claire Mulhearn, 908-236-1118orMerck Investor RelationsJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
NGM And Merck Announce Broad Strategic Collaboration To Discover, Develop And Commercialize Novel Biologic Therapeutics
2015-03-04 04:25:06| drugdiscoveryonline News Articles
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck, known as MSD outside the United States and Canada, recently announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas
Tags: develop
broad
discover
collaboration
Sites : [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] next »